ClinicalTrials.gg
CompletedNCT04958876Updated Jan 31, 2022

Study to Evaluate the Safety of SP-104

A Phase 1 interventional study of SP-104 and Naltrexone immediate release oral capsules in Healthy Volunteers, sponsored by Scilex Pharmaceuticals, Inc.. Completed at 2 sites in New Zealand. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-31.

Sponsored by Scilex Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Evaluate the safety and tolerability of 3-day repeat-dose of SP-104 compared to naltrexone hydrochloride immediate release.

Read the detailed description

The purpose of this trial is to evaluate the safety and tolerability of SP-104 relative to naltrexone immediate release capsules in healthy adults. The study is designed to test the hypothesis that the formulation of SP-104 will mitigate against adverse events associated with naltrexone.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Scilex Pharmaceuticals, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to read, write, and understand the English language and provide English language written (IC) prior to beginning any study procedures.
  2. Male or female age 18 to 70 years (inclusive) at screening.
  3. Medically healthy with no medical history, physical examination, laboratory profiles, vital signs, or (ECG), as deemed by the Investigator.
  4. Negative urine drug screen for drugs of abuse, including cocaine, marijuana, amphetamines, and barbiturates at the Screening Visit and at each check-in.
  5. If female, heterosexually active, of , not pregnant, not trying to become pregnant, or lactating, individuals are eligible to participate if participants agree to total abstinence from heterosexual intercourse, from screening through until at least 30 days after the last study dose, or to the use of an effective method listed below, from screening through until at least 30 days after the last study dose. A second non-hormonal method of is required if a hormonal form of birth control is used. Females of childbearing potential must have negative pregnancy tests at Screening and on admission.
  6. If male and heterosexually active, individuals are eligible to participate if participants agree to total abstinence from heterosexual intercourse, from screening through until at least 90 days after the last study dose, or to the use of an effective method listed below, from screening through until at least 90 days after the last study dose.
  7. Able to swallow capsules.
  8. Agrees to comply with all study requirements throughout the entire study period.

Exclusion criteria

Exclusion Criteria:

  1. A (BMI) \<18 kg/m2 or >30 kg/m2 (without rounding).
  2. Are using prescription medications or over-the-counter products (including dietary supplements such as vitamins, minerals, herbs or other botanicals, amino acids, enzymes (extracts or concentrates), or probiotics (bacteria or yeasts), within 14 days prior to administration of the study medication.
  3. Currently using or have recently used opioids
  4. Use of any other drug within 30 days prior to administration of the study medication.
  5. History of allergic or adverse response to naltrexone.
  6. History of drug or alcohol abuse (>80 g/day).
  7. History of sleep apnea or restless leg syndrome.
  8. Serology positive for surface antigen, antibodies, or (HIV) antibodies.
  9. Positive for known disease (e.g., corona virus disease 2019 (COVID-19 )).
  10. Subjects with current or past SARS-CoV-2 infection, if tested according to local requirements.
  11. Have had a serious illness in the 4 weeks preceding the Screening Visit that resulted in missed work or hospitalization (note: missed work in itself may not denote serious illness).
  12. Have cancer within the past 5 years (treated or untreated).
  13. Are females who are pregnant, plan to become pregnant during the study, or are breastfeeding.
  14. Are an employee, family member, sponsor, or student of the Investigator or of the clinical site.
  15. Are unable to understand or adhere to the requirements of the protocol.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    SP-104 crossover to naltrexone immediate release

    SP-104 administration followed by a crossover to naltrexone immediate release oral capsule administration

    Drug: SP-104 · Drug: Naltrexone immediate release oral capsules

  • Experimental
    Naltrexone immediate release crossover to SP-104

    Naltrexone immediate release oral capsule administration with a crossover to SP-104 administration

    Drug: SP-104 · Drug: Naltrexone immediate release oral capsules

Interventions

  • DrugSP-104

    oral capsule once daily

  • DrugNaltrexone immediate release oral capsules

    oral capsule once daily

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events

    Time frame: 1 week

07

Study locations

2 sites
  • Auckland Clinical Studies (NZCR)
    Auckland, 1010, New Zealand
  • Christchurch Clinical Studies Trust (NZCR)
    Christchurch, 8011, New Zealand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Dec 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2021
First posted
Jul 12, 2021
StartActual
Oct 4, 2021
Primary completionActual
Dec 20, 2021
CompletionActual
Dec 20, 2021
Last update
Jan 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04958876
Lead sponsor
Scilex Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jul 12, 2021
Start date
Oct 4, 2021
Primary completion
Dec 20, 2021
Completion
Dec 20, 2021
Last update
Jan 31, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion